Metformin Combination Therapies Show Cognitive Benefits in Dual-Affected Patients

Strategic Insights -

A study published in the Journal of Alzheimer's Disease has found that combination therapies involving metformin with sulfonylureas or a dipeptidyl peptidase 4 inhibitor (DPP-4i) are associated with a slower rate of cognitive decline in patients with both Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM). Researchers from the University of Pittsburgh analyzed data from the National Alzheimer's Coordinating Center, covering a 17-year period from June 2005 to August 2022. The study included 3234 patients with both AD and T2DM.

Key Takeaways:

  • Combination therapies involving metformin with sulfonylureas (RR = 1.105 [1.022, 1.195], p = 0.013) and metformin with DPP-4i (RR = 1.132 [1.021, 1.256], p = 0.019) slowed down the decline in Mini-Mental State Examination (MMSE) scores in patients with AD and T2DM.
  • Patients receiving metformin with thiazolidinediones (TZD) experienced a faster decline in MMSE scores compared to those receiving metformin with sulfonylureas or DPP-4i.
  • The study demonstrates that specific antidiabetic therapies may have long-term cognitive benefits for patients with dual-affected population.
  • The research provides valuable insights for clinical decision-making in this dual-affected population.
  • The study included 964 patients after applying exclusion criteria, and they were analyzed using propensity score matching and a generalized linear mixed model.
  • Patients were categorized based on their longitudinal use of oral antidiabetic medications.
  • The study concludes that combination therapies involving metformin with sulfonylureas or DPP-4i may be beneficial in slowing down cognitive decline in patients with AD and T2DM.

Statistics:

  • The study included 3234 patients with both AD and T2DM.
  • After applying exclusion criteria, 964 patients were analyzed using propensity score matching and a generalized linear mixed model.
  • The study found that patients receiving metformin with sulfonylureas or DPP-4i experienced a significantly slower decline in MMSE scores (RR = 1.105-1.132, p = 0.013-0.019).
  • The study covered a 17-year period from June 2005 to August 2022.

Sources:

  • NewsRx. New Findings from University of Pittsburgh Yields New Data on Type 2 Diabetes (Impact of antidiabetic therapy on cognitive function in patients with type 2 diabetes and Alzheimer's disease: A comprehensive analysis). Diabetes Week. September 15, 2025; p 396.
  • Impact of antidiabetic therapy on cognitive function in patients with type 2 diabetes and Alzheimer's disease: A comprehensive analysis. Journal of Alzheimer's Disease, 2025:13872877251365662.